265 related articles for article (PubMed ID: 28331003)
1. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Juric D; Krop I; Ramanathan RK; Wilson TR; Ware JA; Sanabria Bohorquez SM; Savage HM; Sampath D; Salphati L; Lin RS; Jin H; Parmar H; Hsu JY; Von Hoff DD; Baselga J
Cancer Discov; 2017 Jul; 7(7):704-715. PubMed ID: 28331003
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Dickler MN; Saura C; Richards DA; Krop IE; Cervantes A; Bedard PL; Patel MR; Pusztai L; Oliveira M; Cardenas AK; Cui N; Wilson TR; Stout TJ; Wei MC; Hsu JY; Baselga J
Clin Cancer Res; 2018 Sep; 24(18):4380-4387. PubMed ID: 29793946
[No Abstract] [Full Text] [Related]
3. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.
Tamura K; Kodaira M; Shimizu C; Yonemori K; Yunokawa M; Shimomura A; Kobayashi T; Nakano K; Tomomatsu J; Ito Y; Tanaka J; Kuriki H; Gu Z; Takahashi S
Cancer Sci; 2018 May; 109(5):1592-1601. PubMed ID: 29500843
[TBL] [Abstract][Full Text] [Related]
6. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
Jhaveri K; Chang MT; Juric D; Saura C; Gambardella V; Melnyk A; Patel MR; Ribrag V; Ma CX; Aljumaily R; Bedard PL; Sachdev JC; Dunn L; Won H; Bond J; Jones S; Savage HM; Scaltriti M; Wilson TR; Wei MC; Hyman DM
Clin Cancer Res; 2021 Jan; 27(2):447-459. PubMed ID: 33148674
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W
Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract][Full Text] [Related]
10. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
11. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
[TBL] [Abstract][Full Text] [Related]
12. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR
Lehmann BD; Abramson VG; Sanders ME; Mayer EL; Haddad TC; Nanda R; Van Poznak C; Storniolo AM; Nangia JR; Gonzalez-Ericsson PI; Sanchez V; Johnson KN; Abramson RG; Chen SC; Shyr Y; Arteaga CL; Wolff AC; Pietenpol JA;
Clin Cancer Res; 2020 May; 26(9):2111-2123. PubMed ID: 31822498
[TBL] [Abstract][Full Text] [Related]
13. A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.
Juric D; de Bono JS; LoRusso PM; Nemunaitis J; Heath EI; Kwak EL; Macarulla Mercadé T; Geuna E; Jose de Miguel-Luken M; Patel C; Kuida K; Sankoh S; Westin EH; Zohren F; Shou Y; Tabernero J
Clin Cancer Res; 2017 Sep; 23(17):5015-5023. PubMed ID: 28490463
[No Abstract] [Full Text] [Related]
14. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in
Pascual J; Lim JSJ; Macpherson IR; Armstrong AC; Ring A; Okines AFC; Cutts RJ; Herrera-Abreu MT; Garcia-Murillas I; Pearson A; Hrebien S; Gevensleben H; Proszek PZ; Hubank M; Hills M; King J; Parmar M; Prout T; Finneran L; Malia J; Swales KE; Ruddle R; Raynaud FI; Turner A; Hall E; Yap TA; Lopez JS; Turner NC
Cancer Discov; 2021 Jan; 11(1):92-107. PubMed ID: 32958578
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.
Abramson VG; Supko JG; Ballinger T; Cleary JM; Hilton JF; Tolaney SM; Chau NG; Cho DC; Pearlberg J; Lager J; Shapiro GI; Arteaga CL
Clin Cancer Res; 2017 Jul; 23(14):3520-3528. PubMed ID: 28031425
[No Abstract] [Full Text] [Related]
16. POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Baird RD; van Rossum AGJ; Oliveira M; Beelen K; Gao M; Schrier M; Mandjes IAM; Garcia-Corbacho J; Vallier AL; Dougall G; van Werkhoven E; Linossi C; Kumar S; van Tinteren H; Callari M; Beddowes E; Perez-Garcia JM; Rosing H; Platte E; Nederlof P; Schot M; de Vries Schultink A; Bernards R; Saura C; Gallagher W; Cortès J; Caldas C; Linn SC
Clin Cancer Res; 2019 Nov; 25(22):6598-6605. PubMed ID: 31439579
[TBL] [Abstract][Full Text] [Related]
17. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
18. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Harding JJ; Bauer TM; Tan DSW; Bedard PL; Rodon J; Doi T; Schnell C; Iyer V; Baffert F; Radhakrishnan R; Fabre C; Juric D
Invest New Drugs; 2019 Apr; 37(2):271-281. PubMed ID: 30073466
[TBL] [Abstract][Full Text] [Related]
19. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
[TBL] [Abstract][Full Text] [Related]
20. A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.
Mateo J; Ganji G; Lemech C; Burris HA; Han SW; Swales K; Decordova S; DeYoung MP; Smith DA; Kalyana-Sundaram S; Wu J; Motwani M; Kumar R; Tolson JM; Rha SY; Chung HC; Eder JP; Sharma S; Bang YJ; Infante JR; Yan L; de Bono JS; Arkenau HT
Clin Cancer Res; 2017 Oct; 23(19):5981-5992. PubMed ID: 28645941
[No Abstract] [Full Text] [Related]
[Next] [New Search]